Real-time PCR, Digital PCR & End-point PCR Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 9.01 Billion
CAGR (2026-2031)	6.46%
Fastest Growing Segment	Clinical
Largest Market	North America
Market Size (2031)	USD 13.12 Billion

Market Overview

The Global Real-time PCR, Digital PCR & End-point PCR Market will grow from USD 9.01 Billion in 2025 to USD 13.12 Billion by 2031 at a 6.46% CAGR. The Global Real-time PCR, Digital PCR & End-point PCR Market comprises advanced nucleic acid amplification technologies utilized for the precise detection and quantification of genetic materials. While real-time PCR enables immediate monitoring and digital PCR provides absolute quantification, end-point PCR remains fundamental for qualitative analysis. Market growth is primarily propelled by the escalating prevalence of infectious diseases and genetic disorders which necessitate rapid, accurate diagnostics. Furthermore, the expanding application of these methodologies in oncology for biomarker detection and the rising demand for personalized medicine serve as distinct drivers supporting widespread adoption across clinical and research sectors.

However, high instrumentation costs and limited diagnostic infrastructure in developing regions present a significant challenge to market expansion. This accessibility gap restricts the universal deployment of molecular testing protocols. According to the World Health Organization, in 2024, rapid molecular tests were utilized as the initial diagnostic tool for only 48% of the 8.2 million people newly diagnosed with tuberculosis in 2023. This statistic underscores the persistent financial and technical barriers that impede the full scalability of PCR-based diagnostics in resource-limited geographies.

Key Market Drivers

The escalating global prevalence of infectious diseases and genetic disorders acts as a primary catalyst for the market, necessitating high-throughput and highly sensitive diagnostic tools. As the burden of chronic conditions like cancer intensifies, the reliance on real-time and digital PCR for biomarker quantification and genetic mutation analysis has surged to support early detection and personalized treatment strategies. For instance, according to the American Cancer Society, January 2024, in the 'Cancer Facts & Figures 2024' report, the projected number of new cancer diagnoses in the United States topped 2 million for the first time in 2024. This rising incidence underscores the critical need for molecular diagnostics in oncology to facilitate precision medicine, thereby sustaining the demand for advanced PCR assays and instrumentation across clinical and research sectors.

Simultaneously, rapid technological advancements in real-time and digital PCR systems are expanding the market's scope through enhanced sensitivity and workflow automation. Leading industry players are heavily investing in research and development to launch innovative platforms that address the complexities of genomic research and clinical diagnostics, enabling the detection of lower-abundance targets. According to Thermo Fisher Scientific, April 2024, in the 'Annual Report 2023', the company invested $1.3 billion in R&D to deliver new technologies, including advanced solutions for specialty diagnostics and life sciences. This commitment to innovation drives the continuous evolution of PCR capabilities, ensuring their applicability in diverse settings. Furthermore, this technological progress translates directly into market performance; according to Roche, in 2023, the Diagnostics Division reported a base business sales increase of 7% at constant exchange rates, reflecting robust demand for non-COVID diagnostic solutions.

Download Free Sample Report

Key Market Challenges

High instrumentation costs and limited diagnostic infrastructure in developing regions significantly hinder the growth of the Global Real-time PCR, Digital PCR & End-point PCR Market. Advanced molecular platforms require substantial upfront capital for equipment and continuous funding for consumables which proves prohibitive for healthcare systems in low-income areas. These financial barriers prevent the widespread installation of PCR platforms in decentralized laboratories and confine the market largely to well-funded urban centers. As a result the industry faces a saturation point in developed nations while failing to penetrate high-growth potential markets in Africa and Asia where infectious disease burdens are highest.

This accessibility gap limits the volume of tests performed and restricts the overall revenue potential for manufacturers. The inability to deploy these technologies at scale means that vast populations remain untested despite the clinical need for accurate detection. According to the World Health Organization, in 2024, only 13% of people living with chronic hepatitis B had been diagnosed globally. This low diagnostic rate demonstrates that financial and technical hurdles prevent the scaling of molecular testing thereby reducing the serviceable market size and slowing the global adoption of PCR technologies.

Key Market Trends

The proliferation of multiplex PCR assays for syndromic pathogen detection is significantly altering diagnostic workflows by enabling the simultaneous identification of numerous targets from a single specimen. This trend addresses the inefficiency of serial testing, particularly for complex clinical presentations such as gastrointestinal infections, meningitis, and sepsis, where identifying the specific causative agent rapidly is critical for patient management. By consolidating multiple tests into one comprehensive panel, laboratories can streamline operations, reduce reagent consumption, and provide faster actionable results compared to traditional single-plex methods. According to bioMérieux, April 2024, in the 'First-Quarter 2024 Business Review', the company reported that sales of its BIOFIRE non-respiratory panels increased by 19% at constant exchange rates compared to the prior year, illustrating the growing market reliance on comprehensive syndromic testing beyond just respiratory applications.

Decentralization of molecular diagnostics via Point-of-Care (POC) PCR systems is expanding the market's reach beyond traditional high-complexity laboratories into near-patient settings. This shift is driven by the development of compact, user-friendly platforms that deliver lab-quality sensitivity with rapid turnaround times, essential for immediate clinical decision-making in urgent care and community clinics. These systems overcome the logistical delays associated with transporting samples to centralized facilities, allowing providers to diagnose and treat infectious diseases during a single patient visit. According to Fierce Biotech, January 2024, in the 'Danaher's 2023 sales drop 10% following transformational year' article, Danaher Corporation revealed that Cepheid’s respiratory diagnostic sales, which leverage the GeneXpert POC platform, reached approximately $650 million in the fourth quarter of 2023 alone, surpassing internal estimates due to robust demand for rapid decentralized testing.

Segmental Insights

The Clinical segment currently represents the fastest-growing category in the Global Real-time PCR, Digital PCR, and End-point PCR Market, driven by the expanding application of molecular diagnostics in patient care. This acceleration is primarily attributed to the rising demand for accurate detection of infectious diseases and genetic disorders. Furthermore, continuous authorizations by regulatory bodies such as the US Food and Drug Administration for new diagnostic assays have significantly facilitated broader adoption. Consequently, diagnostic laboratories and hospitals are increasingly integrating these methods to ensure precise diagnosis and effective treatment planning for various medical conditions.

Regional Insights

North America maintains a dominant position in the global market for Real-time, Digital, and End-point PCR technologies due to extensive research and development initiatives supported by substantial government funding. Institutions such as the National Institutes of Health actively finance genomic research, fostering widespread technology adoption across the region. Furthermore, the presence of established biotechnology companies facilitates the rapid commercialization of diagnostic assays. The region also benefits from a well-defined regulatory framework managed by the U.S. Food and Drug Administration, which streamlines product approvals and supports continuous market expansion for clinical diagnostics.

Recent Developments

In July 2025, Bio-Rad Laboratories launched four new digital PCR platforms, significantly expanding its hardware portfolio for life science research and clinical diagnostics. The release included the QX Continuum system and the QX700 series, which were integrated into the company's offerings following the strategic acquisition of Stilla Technologies earlier in the year. These new instruments provided advanced multiplexing capabilities, allowing for the precise detection of multiple biological targets in a single reaction. The expanded product line was designed to address growing demands in oncology and genetic research by offering improved workflow simplicity and higher throughput for laboratory professionals.
In November 2024, Takara Bio USA introduced the SmartChip ND Real-Time PCR System, a high-throughput automated solution designed to advance infectious disease research and antimicrobial resistance monitoring. The newly released system featured nanoliter-scale reactions that eliminated the need for preamplification steps, thereby reducing reagent costs and experimental variability. It was capable of processing over 5,000 reactions per chip, offering research laboratories a scalable and flexible platform for analyzing large panels of genetic targets. This launch addressed the critical market need for cost-effective and efficient surveillance tools in both clinical and environmental research settings.
In September 2024, Roche announced the global launch of the cobas Respiratory flex test, the first diagnostic assay to utilize its proprietary TAGS technology. This innovative multiplex real-time PCR solution enabled the simultaneous detection of up to 15 pathogens, including influenza and SARS-CoV-2, in a single test run. The technology allowed laboratories to perform comprehensive syndromic testing on existing high-throughput analyzers without requiring additional hardware upgrades. The launch aimed to improve patient care by providing clinicians with faster and more accurate diagnoses for respiratory illnesses, particularly during peak viral seasons when symptoms often overlap.
In June 2024, QIAGEN expanded its digital PCR portfolio by launching 35 new wet-lab tested assays for the QIAcuity platform, specifically targeting microbial DNA detection. These additions extended the company’s offerings to include tests for pathogens responsible for tropical diseases, sexually transmitted infections, and urinary tract infections. The assays were developed to provide precise and absolute quantification of microbial targets, facilitating advanced research into infectious diseases and public health surveillance. This strategic expansion aimed to support the scientific community by offering robust tools for identifying and monitoring critical microbial threats with enhanced sensitivity and specificity.

Key Market Players

Abbott Laboratories Inc
Bio-Rad Laboratories Inc.
Thermo Fisher Scientific, Inc.
BIOMÉRIEUX SA
Fluidigm Corporation
F. Hoffmann-La Roche Ltd
GE Healthcare
Agilent Technologies, Inc.
Qiagen NV
Microsynth Ag

By Technology	By Product	By Application	By Region
Quantitative Digital Endpoint	Consumables & Reagents Instruments Software & Services	Clinical Research	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Real-time PCR, Digital PCR & End-point PCR Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Real-time PCR, Digital PCR & End-point PCR Market, By Technology:

Quantitative
Digital
Endpoint

Real-time PCR, Digital PCR & End-point PCR Market, By Product:

Consumables & Reagents
Instruments
Software & Services

Real-time PCR, Digital PCR & End-point PCR Market, By Application:

Clinical
Research

Real-time PCR, Digital PCR & End-point PCR Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Real-time PCR, Digital PCR & End-point PCR Market.

Available Customizations:

Global Real-time PCR, Digital PCR & End-point PCR Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Real-time PCR, Digital PCR & End-point PCR Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Real-time PCR, Digital PCR & End-point PCR Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Technology (Quantitative, Digital, Endpoint)

5.2.2. By Product (Consumables & Reagents, Instruments, Software & Services)

5.2.3. By Application (Clinical, Research)

5.2.4. By Region

5.2.5. By Company (2025)

5.3. Market Map

6. North America Real-time PCR, Digital PCR & End-point PCR Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Technology

6.2.2. By Product

6.2.3. By Application

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Real-time PCR, Digital PCR & End-point PCR Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Technology

6.3.1.2.2. By Product

6.3.1.2.3. By Application

6.3.2. Canada Real-time PCR, Digital PCR & End-point PCR Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Technology

6.3.2.2.2. By Product

6.3.2.2.3. By Application

6.3.3. Mexico Real-time PCR, Digital PCR & End-point PCR Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Technology

6.3.3.2.2. By Product

6.3.3.2.3. By Application

7. Europe Real-time PCR, Digital PCR & End-point PCR Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Technology

7.2.2. By Product

7.2.3. By Application

7.2.4. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Real-time PCR, Digital PCR & End-point PCR Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Technology

7.3.1.2.2. By Product

7.3.1.2.3. By Application

7.3.2. France Real-time PCR, Digital PCR & End-point PCR Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Technology

7.3.2.2.2. By Product

7.3.2.2.3. By Application

7.3.3. United Kingdom Real-time PCR, Digital PCR & End-point PCR Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Technology

7.3.3.2.2. By Product

7.3.3.2.3. By Application

7.3.4. Italy Real-time PCR, Digital PCR & End-point PCR Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Technology

7.3.4.2.2. By Product

7.3.4.2.3. By Application

7.3.5. Spain Real-time PCR, Digital PCR & End-point PCR Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Technology

7.3.5.2.2. By Product

7.3.5.2.3. By Application

8. Asia Pacific Real-time PCR, Digital PCR & End-point PCR Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Technology

8.2.2. By Product

8.2.3. By Application

8.2.4. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Real-time PCR, Digital PCR & End-point PCR Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Technology

8.3.1.2.2. By Product

8.3.1.2.3. By Application

8.3.2. India Real-time PCR, Digital PCR & End-point PCR Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Technology

8.3.2.2.2. By Product

8.3.2.2.3. By Application

8.3.3. Japan Real-time PCR, Digital PCR & End-point PCR Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Technology

8.3.3.2.2. By Product

8.3.3.2.3. By Application

8.3.4. South Korea Real-time PCR, Digital PCR & End-point PCR Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Technology

8.3.4.2.2. By Product

8.3.4.2.3. By Application

8.3.5. Australia Real-time PCR, Digital PCR & End-point PCR Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Technology

8.3.5.2.2. By Product

8.3.5.2.3. By Application

9. Middle East & Africa Real-time PCR, Digital PCR & End-point PCR Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Technology

9.2.2. By Product

9.2.3. By Application

9.2.4. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Real-time PCR, Digital PCR & End-point PCR Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Technology

9.3.1.2.2. By Product

9.3.1.2.3. By Application

9.3.2. UAE Real-time PCR, Digital PCR & End-point PCR Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Technology

9.3.2.2.2. By Product

9.3.2.2.3. By Application

9.3.3. South Africa Real-time PCR, Digital PCR & End-point PCR Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Technology

9.3.3.2.2. By Product

9.3.3.2.3. By Application

10. South America Real-time PCR, Digital PCR & End-point PCR Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Technology

10.2.2. By Product

10.2.3. By Application

10.2.4. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Real-time PCR, Digital PCR & End-point PCR Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Technology

10.3.1.2.2. By Product

10.3.1.2.3. By Application

10.3.2. Colombia Real-time PCR, Digital PCR & End-point PCR Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Technology

10.3.2.2.2. By Product

10.3.2.2.3. By Application

10.3.3. Argentina Real-time PCR, Digital PCR & End-point PCR Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Technology

10.3.3.2.2. By Product

10.3.3.2.3. By Application

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Real-time PCR, Digital PCR & End-point PCR Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Abbott Laboratories Inc

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Bio-Rad Laboratories Inc.

15.3. Thermo Fisher Scientific, Inc.

15.4. BIOMÉRIEUX SA

15.5. Fluidigm Corporation

15.6. F. Hoffmann-La Roche Ltd

15.7. GE Healthcare

15.8. Agilent Technologies, Inc.

15.9. Qiagen NV

15.10. Microsynth Ag

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Real-time PCR, Digital PCR & End-point PCR Market in 2025?

Which is the dominating region in the Global Real-time PCR, Digital PCR & End-point PCR Market?

Which is the fastest growing segment in the Global Real-time PCR, Digital PCR & End-point PCR Market?

What is the expected growth rate of the Global Real-time PCR, Digital PCR & End-point PCR Market?